Keyword Analysis & Research: v600e braf mutation melanoma


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
v600e braf mutation melanoma1.190.765982328
v600e0.130.99778305
braf0.370.19178424
mutation1.060.8490188
melanoma1.820.59273538

Keyword Research: People who searched v600e braf mutation melanoma also searched

Keyword CPC PCC Volume Score
v600e braf mutation melanoma1.40.920263

Search Results related to v600e braf mutation melanoma on Search Engine

  • BRAF V600E -mutant metastatic NSCLC: disease overview and …

    nature.com

    https://www.nature.com/articles/s41698-024-00552-7

    WebApr 16, 2024 · Mutations in the v-Raf murine sarcoma viral oncogene homolog B ( BRAF) gene have been found in ~4–8% of all cancers, with the greatest number found in colorectal cancer (CRC),...

    DA: 47 PA: 44 MOZ Rank: 69

  • A B‐Raf V600E gene signature for melanoma predicts prognosis …

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855909/

    WebJan 19, 2022 · B‐Raf V600E mutations account for about half of all skin cutaneous melanoma cases, and patients with this mutation are sensitive to BRAF inhibitors. However, aberrations in other genes in the MAPK/ERK pathway may cascade a similar effect as B‐Raf V600E mutations, rendering those patients sensitive to BRAF inhibitors.

    DA: 49 PA: 73 MOZ Rank: 23

  • Immunotherapy Combination for BRAF+ Melanoma - NCI

    cancer.gov

    https://www.cancer.gov/news-events/cancer-currents-blog/2021/advanced-melanoma-braf-immunotherapy-first

    WebDec 17, 2021 · Both drug combinations have been found to be effective in people with advanced melanoma. But for the estimated 50% of people whose melanomas have a BRAF V600 mutation, researchers didn’t know which treatment combination was better to use first. For these patients, there now appears to be an answer.

    DA: 51 PA: 26 MOZ Rank: 89

  • BRAF Mutations in Melanoma: Biological Aspects, Therapeutic

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452867/

    WebAug 8, 2023 · The most frequent oncogenic BRAF mutations consist of a single point mutation at codon 600 (mostly V600E) that leads to constitutive activation of the BRAF/MEK/ERK (MAPK) signalling pathway. Therefore, mutated BRAF has become a useful target for molecular therapy and the use of BRAF kinase inhibitors has shown …

    DA: 85 PA: 34 MOZ Rank: 3

  • BRAF Gene and Melanoma: Back to the Future - PMC

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037827/

    WebMar 27, 2021 · To date, two largely mutually exclusive groups of cutaneous melanomas can be categorised: those harbouring an activating BRAF mutation (mostly BRAF V600E), which represent 40–50% of all melanoma patients, and those harbouring other mutations than BRAF [ 2 ].

    DA: 96 PA: 80 MOZ Rank: 25

  • Triple therapy for BRAFV600-mutated melanoma - The Lancet

    thelancet.com

    https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31285-X/fulltext

    WebJun 13, 2020 · There is a need to improve on the remarkable advances in the treatment of patients with metastatic melanoma driven by oncogenic BRAFV600 mutations, as only a third to half of patients derive long-term benefit. , , , , Effectively combining the benefits of BRAF inhibitor-based targeted therapy with immune checkpoint blockade has been a …

    DA: 74 PA: 98 MOZ Rank: 28

  • Molecular testing for BRAF mutations to inform melanoma treatment

    nature.com

    https://www.nature.com/articles/modpathol2017104

    WebNov 17, 2017 · Approximately one-half of advanced (unresectable or metastatic) melanomas harbor a mutation in the BRAF gene, with V600E being the most common mutation. Targeted therapy with BRAF and MEK...

    DA: 40 PA: 65 MOZ Rank: 41

  • Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

    nejm.org

    https://www.nejm.org/doi/full/10.1056/NEJMoa1203421

    WebJul 12, 2012 · In this phase 3 open-label trial, we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation to receive either trametinib, an oral selective MEK...

    DA: 39 PA: 58 MOZ Rank: 76

  • Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

    nejm.org

    https://www.nejm.org/doi/full/10.1056/NEJMoa1103782

    WebJun 30, 2011 · Vemurafenib (PLX4032) is a potent inhibitor of mutated BRAF. 12 It has marked antitumor effects against melanoma cell lines with the BRAF V600E mutation but not against cells with...

    DA: 65 PA: 88 MOZ Rank: 19

  • Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

    nejm.org

    https://www.nejm.org/doi/full/10.1056/NEJMoa1210093

    WebNov 1, 2012 · The use of vemurafenib and dabrafenib, agents that block MAPK signaling in patients with melanoma and the BRAF V600E mutation, has been associated with prolonged survival and...

    DA: 95 PA: 16 MOZ Rank: 56